...
首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis
【24h】

Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis

机译:降低透析液钙水平可降低血液透析患者冠状动脉钙化的进展并改善低骨周转率

获取原文

摘要

Exposure to high Ca concentrations may influence the development of low–turnover bone disease and coronary artery calcification (CAC) in patients on hemodialysis (HD). In this randomized, controlled study, we investigated the effects of lowering dialysate Ca level on progression of CAC and histologic bone abnormalities in patients on HD. Patients on HD with intact parathyroid hormone levels ≤300 pg/ml receiving dialysate containing 1.75 or 1.50 mmol/L Ca ( n =425) were randomized to the 1.25-mmol/L Ca (1.25 Ca; n =212) or the 1.75-mmol/L Ca (1.75 Ca; n =213) dialysate arm. Primary outcome was a change in CAC score measured by multislice computerized tomography; main secondary outcome was a change in bone histomorphometric parameters determined by analysis of bone biopsy specimens. CAC scores increased from 452±869 (mean±SD) in the 1.25 Ca group and 500±909 in the 1.75 Ca group ( P =0.68) at baseline to 616±1086 and 803±1412, respectively, at 24 months ( P =0.25). Progression rate was significantly lower in the 1.25 Ca group than in the 1.75 Ca group ( P =0.03). The prevalence of histologically diagnosed low bone turnover decreased from 85.0% to 41.8% in the 1.25 Ca group ( P =0.001) and did not change in the 1.75 Ca group. At 24 months, bone formation rate, trabecular thickness, and bone volume were higher in the 1.25 Ca group than in the 1.75 Ca group. Thus, lowering dialysate Ca levels slowed the progression of CAC and improved bone turnover in patients on HD with baseline intact parathyroid hormone levels ≤300 pg/ml.
机译:血液透析(HD)患者暴露于高钙浓度下可能会影响低周转性骨病和冠状动脉钙化(CAC)的发展。在这项随机对照研究中,我们研究了降低透析液Ca水平对HD患者CAC进展和组织学骨异常的影响。 HD的完整甲状旁腺激素水平≤300pg / ml的患者接受包含1.75或1.50 mmol / L Ca(n = 425)的透析液,随机分配至1.25 mmol / L Ca(1.25 Ca; n = 212)或1.75- mmol / L Ca(1.75 Ca; n = 213)透析液臂。主要结果是通过多层计算机断层摄影术测得的CAC评分变化。主要的次要结果是通过骨活检标本的分析确定的骨组织形态学参数的变化。 CAC评分从基线时的1.25 Ca组的452±869(平均值±SD)和1.75 Ca组的500±909(P = 0.68)在基线时分别提高至616±1086和803±1412(P = 0.25)。 1.25 Ca组的进展速度显着低于1.75 Ca组(P = 0.03)。经组织学诊断为低骨转换的患病率在1.25 Ca组中从85.0%降至41.8%(P = 0.001),而在1.75 Ca组中没有变化。在24个月时,1.25 Ca组的骨形成率,小梁厚度和骨量高于1.75 Ca组。因此,降低基线基线完整甲状旁腺激素水平≤300pg / ml的HD患者的透析液Ca水平降低会减慢CAC的进展并改善骨转换。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号